Systemically delivered antisense oligomers upregulate gene expression in mouse tissues

Nature Biotechnology

Volumn 20, Issue 12, 2002, Pages 1228-1233

  Sazani, Peter ^a,b   Gemignani, Federica ^a   Kang, Shin Hong ^a   Maier, Martin A ^c   Manoharan, Muthiah ^c   Persmark, Magnus ^d   Bortner, Donna ^d   Kole, Ryszard ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c ISIS PHARMACEUTICALS   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; FLUORESCENCE; IMMUNOLOGY; OLIGOMERS; PROTEINS; TISSUE;

ANTISENSE ACTIVITY;

GENETIC ENGINEERING;

2' O METHOXYETHYL PHOSPHOROTHIOATE; ANTISENSE OLIGONUCLEOTIDE; BETA GLOBIN; GREEN FLUORESCENT PROTEIN; LYSINE; MESSENGER RNA; MORPHOLINE DERIVATIVE; OLIGOMER; PEPTIDE NUCLEIC ACID; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; FIBROBLAST; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; INTRON; LIVER CELL; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; ANIMAL; ANTIBODY SPECIFICITY; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; GENE THERAPY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METHODOLOGY; PHYSIOLOGY; UPREGULATION;

ANIMALS; CELLS, CULTURED; FIBROBLASTS; GENE EXPRESSION REGULATION; GENE THERAPY; INJECTIONS, INTRAVENOUS; LIVER; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES, ANTISENSE; ORGAN SPECIFICITY; PEPTIDE NUCLEIC ACIDS; TISSUE DISTRIBUTION; UP-REGULATION;

EID: 0036903132     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt759     Document Type: Article

References (34)

1. Lander, E. S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860-921 (2001).
2. Venter, J. C. et al. The sequence of the human genome. Science 291, 1304-1351 (2001).
3. Graveley, B. R. Alternative splicing: Increasing diversity in the proteomic world. Trends Genet. 17, 100-107 (2001).
4. Mercatante, D. & Kole, R. Modification of alternative splicing pathways as a potential approach to chemotherapy. Pharmacol. Ther. 85, 237-243 (2000).
5. Kole, R. & Sazani, P. Antisense effects in the cell nucleus: Modification of splicing. Curr. Opin. Mol. Ther. 3, 229-234 (2001).
6. Mercatante, D. R., Bortner, C. D., Cidlowski, J. A. & Kole, R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. Analysis of apoptosis and cell death. J. Biol. Chem. 276, 16411-16417 (2001).
7. Taylor, J. K., Zhang, Q. Q., Wyatt, J. R. & Dean, N. M. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat. Biotechnol. 17, 1097-1100 (1999).
8. Friedman, K. J. et al. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J. Biol. Chem. 274, 36193-36199 (1999).
9. Dunckley, M. G., Manoharan, M., Villiet, P., Eperon, I. C. & Dickson, G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum. Mol. Genet. 7, 1083-1090 (1998).
10. Wilton, S. D. etal. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul. Disord. 9, 330-338 (1999).
11. Kalbfuss, B., Mabon, S. A. & Misteli, T. Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17. J. Biol. Chem. 276, 42986-42993 (2001).
12. Karras, J. G., McKay, R. A., Dean, N. M. & Monia, B. P. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-α chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. Mol. Pharmacol. 58, 380-387 (2000).
13. Suwanmanee, T. et al. Restoration of human β-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol. Pharmacol. 62, 545-553 (2002).
14. Lacerra, G. et al. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA 97, 9591-9596 (2000).
15. Tamm, I., Dorken, B. & Hartmann, G. Antisense therapy in oncology: New hope for an old idea? Lancet 358, 489-497 (2001).
16. Juliano, R. L., Alahari, S., Yoo, H., Kole, R. & Cho, M. Antisense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides. Pharm. Res. 16, 494-502 (1999).
17. Marcusson, E. G., Yacyshyn, B. R., Shanahan, W. R., Jr. & Dean, N. M. Preclinical and clinical pharmacology of antisense oligonucleotides. Mol. Biotechnol. 12, 1-11 (1999).
18. Lebedeva, I. & Stein, C. A. Antisense oligonucleotides: Promise and reality. Annu. Rev. Pharmacol. Toxicol. 41, 403-419 (2001).
19. Mercatante, D., Sazani, P. & Kole, R. Modification of alternative splicing pathways as a potential chemotherapy for cancer and other diseases. Curr. Cancer Drug Targets 1, 211-230 (2001).
20. Geary, R. S. et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther. 296, 890-897 (2001).
21. Sazani, P. et al. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. Nucleic Acids Res. 29, 3965-3974 (2001).
22. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as a source of ubiquitous green cells. FEBS Lett. 407, 313-319 (1997).
23. McMahon, B. M. et al. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 12, 65-70 (2002).
24. Agrawal, S., Temsamani, J. & Tang, J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88, 7595-7599 (1991).
25. Arora, V., Knapp, D. C., Reddy, M. T., Weller, D. D. & Iversen, P. L. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci. 91, 1009-1018 (2002).
26. Zhang, H. et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18, 862-867 (2000).
27. Mehta, R. C. et al. Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides. J. Invest. Dermatol. 115, 805-812 (2000).
28. Brand, R. M. & Iversen, P. L. Transdermal delivery of antisense compounds. Adv. Drug. Deliv. Rev. 44, 51-57 (2000).
29. DeLong, R. K. et al. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev. 7, 71-77 (1997).
30. Agrawal, S., Temsamani, J., Galbraith, W. & Tang, J. Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28, 7-16 (1995).
31. Geary, R. S. et al. Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. J. Pharmacol. Exp. Ther. 296, 898-904 (2001).
32. Qin, G., Taylor, M., Ning, Y. Y., Iversen, P. & Kobzik, L. In vivo evaluation of a morpholino antisense oligomer directed against tumor necrosis factor-α. Antisense Nucleic Acid Drug Dev. 10, 11-16 (2000).
33. Corey, D. R. & Abrams, J. M. Morpholino antisense oligonucleotides: Tools for investigating vertebrate development. Genome Biol. 2, REVIEWS1015 (2001).
34. Sierakowska, H., Sambade, M. J., Agrawal, S. & Kole, R. Repair of thalassemic human β-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 93, 12840-12844 (1996).